Peptide Marketing Report
Peptides carry the sharpest enforcement edge of any vertical we cover, and the reason is regulatory, not medical. Much of the category lives in an FDA grey zone shaped by 503A and 503B compounding rules and by products marketed as research use only. This hub tracks that grey zone each quarter and keeps the latest edition on top.
What draws letters here is the gap between what a compound is approved for and how it gets marketed. A compound moving off the compounding lists, a research-use-only label doing consumer-marketing work, a claim the evidence does not carry: these are the patterns the record shows. The reports separate what is defensible from what is not, and where local demand is still winnable.
Latest edition · Q2 2026
Peptide Marketing, Q2 2026: Enforcement, Search Demand, and AI Visibility
Read the Q2 2026 edition →Other reports
Healthcare Marketing and Compliance Report
The cross-vertical flagship. FDA and FTC enforcement trends alongside search demand and AI-assistant visibility across every regulated healthcare vertical we track.
GLP-1 and Weight Loss Marketing Report
The gold rush and the crackdown. Where GLP-1 and weight-loss demand is going, how enforcement is tightening, and which brands own the AI answers.
TRT and Hormone Marketing Report
Hormone optimization sits next to a grey market of SARMs and compounded products. Where demand is, where the enforcement edge is, and who wins AI answers.
Medical Spa and Aesthetics Marketing Report
The most local game in aesthetics. Where med-spa demand concentrates, how product-linked claims draw letters, and how much local ground is still open.
Every edition is drawn from the Authoritize Atlas, our corpus of FDA and FTC actions, and from live search and AI-citation measurement. Screen your own marketing against the same rules with the free Claim Checker.